CN107793481A - 一种靶向人cd123的嵌合受体配体及其应用 - Google Patents

一种靶向人cd123的嵌合受体配体及其应用 Download PDF

Info

Publication number
CN107793481A
CN107793481A CN201610795955.XA CN201610795955A CN107793481A CN 107793481 A CN107793481 A CN 107793481A CN 201610795955 A CN201610795955 A CN 201610795955A CN 107793481 A CN107793481 A CN 107793481A
Authority
CN
China
Prior art keywords
seq
chimeric receptor
receptor ligand
targeting human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610795955.XA
Other languages
English (en)
Chinese (zh)
Inventor
庄秋传
范晓虎
杨蕾
王平艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Priority to CN201610795955.XA priority Critical patent/CN107793481A/zh
Priority to JP2019531525A priority patent/JP6990244B2/ja
Priority to US16/329,739 priority patent/US11401317B2/en
Priority to PCT/CN2017/099941 priority patent/WO2018041220A1/zh
Priority to EP17845522.6A priority patent/EP3508504A4/en
Publication of CN107793481A publication Critical patent/CN107793481A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201610795955.XA 2016-08-31 2016-08-31 一种靶向人cd123的嵌合受体配体及其应用 Pending CN107793481A (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201610795955.XA CN107793481A (zh) 2016-08-31 2016-08-31 一种靶向人cd123的嵌合受体配体及其应用
JP2019531525A JP6990244B2 (ja) 2016-08-31 2017-08-31 ヒトcd123を標的とするキメラ受容体リガンド及びその応用
US16/329,739 US11401317B2 (en) 2016-08-31 2017-08-31 Human-CD123-targeting chimeric receptor ligand and application thereof
PCT/CN2017/099941 WO2018041220A1 (zh) 2016-08-31 2017-08-31 一种靶向人cd123的嵌合受体配体及其应用
EP17845522.6A EP3508504A4 (en) 2016-08-31 2017-08-31 CHIMERIC RECEPTOR LIGAND TARGETING HUMAN CD123 AND ITS APPLICATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610795955.XA CN107793481A (zh) 2016-08-31 2016-08-31 一种靶向人cd123的嵌合受体配体及其应用

Publications (1)

Publication Number Publication Date
CN107793481A true CN107793481A (zh) 2018-03-13

Family

ID=61300124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610795955.XA Pending CN107793481A (zh) 2016-08-31 2016-08-31 一种靶向人cd123的嵌合受体配体及其应用

Country Status (5)

Country Link
US (1) US11401317B2 (cg-RX-API-DMAC7.html)
EP (1) EP3508504A4 (cg-RX-API-DMAC7.html)
JP (1) JP6990244B2 (cg-RX-API-DMAC7.html)
CN (1) CN107793481A (cg-RX-API-DMAC7.html)
WO (1) WO2018041220A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
CN110157678A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
CN110904048A (zh) * 2019-12-04 2020-03-24 合肥中科干细胞再生医学有限公司 一种car-cd123t2嵌合抗原受体t细胞及其应用
CN115819622A (zh) * 2022-09-26 2023-03-21 湖南省人民医院(湖南师范大学附属第一医院) 针对b系白血病或淋巴瘤的双靶点car结构及药物组合物
CN117659196A (zh) * 2023-12-12 2024-03-08 成都优赛诺生物科技有限公司 一种靶向cd7的单域抗体、嵌合抗原受体及其应用
CN117964783A (zh) * 2024-02-05 2024-05-03 浙江康佰裕生物科技有限公司 一种靶向cll1的嵌合抗原受体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
WO2023000036A1 (en) * 2021-07-22 2023-01-26 The Westmead Institute for Medical Research Chimeric antigen receptor useful in treating cancer
WO2023010126A2 (en) * 2021-07-29 2023-02-02 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
CN117126856A (zh) * 2022-05-20 2023-11-28 上海雅科生物科技有限公司 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104769103A (zh) * 2012-09-04 2015-07-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
WO2016028896A1 (en) * 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207941B3 (en) * 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
TR201910814T4 (tr) * 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
EP3158064A1 (en) * 2014-06-17 2017-04-26 Cellectis Cd123 specific multi-chain chimeric antigen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104769103A (zh) * 2012-09-04 2015-07-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
WO2016028896A1 (en) * 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARMEN MARDIROS, ET AL.: ""T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia"", 《CURR OPIN HEMATOL》 *
BAXTER,E.W., ET AL.: ""interleukin-3 precursor [Homo sapiens],NP_000579.2,152 aa"", 《NCBI GENBANK》 *
RADHIKA THOKALA, ET AL.: ""Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors"", 《PLOS ONE》 *
张砚君 等: ""IL-3-LDM融合蛋白对CD123+白血病细胞的靶向杀伤作用"", 《中国肿瘤生物治疗杂质》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110157678A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
CN110904048A (zh) * 2019-12-04 2020-03-24 合肥中科干细胞再生医学有限公司 一种car-cd123t2嵌合抗原受体t细胞及其应用
CN115819622A (zh) * 2022-09-26 2023-03-21 湖南省人民医院(湖南师范大学附属第一医院) 针对b系白血病或淋巴瘤的双靶点car结构及药物组合物
CN117659196A (zh) * 2023-12-12 2024-03-08 成都优赛诺生物科技有限公司 一种靶向cd7的单域抗体、嵌合抗原受体及其应用
CN117964783A (zh) * 2024-02-05 2024-05-03 浙江康佰裕生物科技有限公司 一种靶向cll1的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
US20190225668A1 (en) 2019-07-25
WO2018041220A1 (zh) 2018-03-08
EP3508504A4 (en) 2020-04-22
JP6990244B2 (ja) 2022-01-12
US11401317B2 (en) 2022-08-02
EP3508504A1 (en) 2019-07-10
JP2019532668A (ja) 2019-11-14

Similar Documents

Publication Publication Date Title
JP6990244B2 (ja) ヒトcd123を標的とするキメラ受容体リガンド及びその応用
US11564945B2 (en) Chimeric antigen receptor and use thereof
US20260062712A1 (en) Optimized lentiviral transfer vectors and uses thereof
CN112142854B (zh) 免疫调节特异性嵌合抗原受体细胞及制备方法和应用
EP3664835B1 (en) Methods and compositions for preparing genetically engineered cells
CA3173394A1 (en) Methods of making chimeric antigen receptor-expressing cells
AU2020418199A1 (en) Modified immune effector cell and preparation method therefor
CN110087672A (zh) 免疫调节多肽及相关组合物和方法
JP2017518037A (ja) 導入遺伝子の遺伝子タグおよびその使用方法
EP2884999A1 (en) Method and compositions for cellular immunotherapy
WO2023109257A1 (zh) 人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
CN113039206A (zh) 包含b7h3嵌合抗原受体的方法和组合物
WO2018111340A1 (en) Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
JP2021533747A (ja) 組み込まれた核酸を評価するための方法
CA3229746A1 (en) Methods of making chimeric antigen receptor-expressing cells
WO2024140778A1 (zh) Nkg2d工程化细胞及其组合物
US20240033357A1 (en) Chimeric antigen receptors and uses thereof
CN112500497B (zh) Cltx-nkg2d双特异性嵌合抗原受体细胞及其制备方法和应用
WO2024193714A1 (zh) 细胞免疫疗法的组合物和方法
HK40041592A (en) Human-cd123-targeting chimeric receptor ligand and application thereof
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
AU2024316791A1 (en) Chimeric ilt receptor compositions and methods
CN118812723A (zh) 融合蛋白及其应用
EP4547704A1 (en) Chimeric checkpoint receptor for the use in treatment of malignant b-cell diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180313

RJ01 Rejection of invention patent application after publication